Skip to main content
Home / Annals of Surgery, Volume 264, Number 5

Esophageal Adenocarcinoma

Buy Article:

$57.00 + tax (Refund Policy)

Objective:

To evaluate complete tumor resection rate (primary objective), 30-day postoperative outcomes, and survival (secondary objectives) in patients with a hiatal hernia (HH) ≥5 cm (HH group) compared with those who did not have a HH or presented with a HH <5 cm (control group).Background:

HH is a risk factor for esophageal and junctional adenocarcinoma (EGJA). Its impact on the outcomes after EGJA surgery is unknown.Methods:

Among 367 patients who underwent surgery for EGJA, a HH was searched for on computerized tomography scan and barium swallow, with comparison between the HH (n = 42) and control (n = 325) groups.Results:

In the HH group, EGJAs exhibited higher rates of incomplete resection (50.0% vs 4.0%; P < 0.001), of pN3 stages (28.5% vs 10.1%; P = 0.002), and lower median survival (20.9 vs 41.0 mos; P = 0.001). After adjustment, a HH ≥5 cm was a predictor of incomplete resection (odds ratio 21.0, 95% confidence interval 9.4–46.8, P < 0.001) and a poor prognostic factor (hazard ratio 1.6, 95% confidence interval 1.1–2.5, P = 0.025). In the HH group, 30-day mortality was significantly higher in patients who received neoadjuvant radiotherapy (20.0% vs 0%; P = 0.040), which was related to greater cardiac and pulmonary toxicity.Conclusions:

For the first time, we showed that a HH ≥5 cm is associated with a poor prognosis in patients who had surgery for EGJA, linked to greater incomplete resection and lymph node involvement. Neoadjuvant radiotherapy was associated with a significant toxicity in patients with a HH ≥5 cm.

Keywords: chemoradiotherapy; esophageal adenocarcinoma; hiatal hernia; mortality; surgery; survival

Document Type: Research Article

Affiliations: 1: Univ.Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France 2: Univ.Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, Univ.Lille, URM-S 1172 – JPArc – Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France, Inserm, UMR-S 1172, Lille, France 3: Univ.Lille, URM-S 1172 – JPArc – Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France, Inserm, UMR-S 1172, Lille, France, Univ.Lille, Department of Pathology, Centre de Biologie et Pathologie, University Hospital, Lille, France, SIRIC ONCOLille, Lille, France 4: Univ.Lille, URM-S 1172 – JPArc – Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France, Univ.Lille, Department of Radiology, Claude Huriez University Hospital, University Hospital, Lille, France 5: Univ.Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, Univ.Lille, URM-S 1172 – JPArc – Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France 6: Univ.Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, Univ.Lille, URM-S 1172 – JPArc – Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France, Inserm, UMR-S 1172, Lille, France, SIRIC ONCOLille, Lille, France 7: Department of Gastrointestinal Oncology, Oscar Lambret Center, Lille, France 8: Department of Gastrointestinal Oncology, Oscar Lambret Center, Lille, France, Department of Radiation Oncology, Oscar Lambret Center, Lille, France. 9: Univ.Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France, Univ.Lille, URM-S 1172 – JPArc – Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France, Inserm, UMR-S 1172, Lille, France, SIRIC ONCOLille, Lille, France

Publication date: 01 November 2016

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content